Regeneron Pharmaceuticals (REGN) has revealed that the independent data monitoring committee (IDMC) has advised it to modify its current REGN-COV2 antibody cocktail treatment trials …
Sanofi (SNYNF) and Regeneron have announced that a pivotal Phase 3 trial of Dupixent (dupilumab) met its primary and all key secondary endpoints in children …
Regeneron Pharmaceuticals (REGN) has now announced the pricing of an underwritten offering of $1.250 billion aggregate principal amount of senior unsecured notes due …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) announced that the European Medicine Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …
Managing cholesterol is a private, emotional fight against a condition that cannot be seen or felt.1 Now, a new film highlights individuals around …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that Bayer HealthCare’sJapanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA® (aflibercept) Injection by the Ministry of Health, Labour and …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced the winners of the third annual Regeneron Prize for Creative Innovation, an award designed to acknowledge, reward and foster talented …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that NASDAQ has halted trading of the company’s common stock. The Endocrinologic and Metabolic Drugs Advisory Committee of the …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary …
In a research report sent to investors today, Deutsche Bank analyst Robyn Karnauskas maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a …